| Literature DB >> 31956038 |
Zhe Zhu1, Pinar Mesci2, Jean A Bernatchez3, Ryan C Gimple4, Xiuxing Wang1, Simon T Schafer5, Hiromi I Wettersten6, Sungjun Beck3, Alex E Clark7, Qiulian Wu1, Briana C Prager8, Leo J Y Kim9, Rekha Dhanwani10, Sonia Sharma10, Alexandra Garancher11, Sara M Weis6, Stephen C Mack12, Priscilla D Negraes13, Cleber A Trujillo13, Luiz O Penalva14, Jing Feng15, Zhou Lan15, Rong Zhang16, Alex W Wessel16, Sanjay Dhawan17, Michael S Diamond16, Clark C Chen17, Robert J Wechsler-Reya11, Fred H Gage5, Hongzhen Hu15, Jair L Siqueira-Neto18, Alysson R Muotri19, David A Cheresh20, Jeremy N Rich21.
Abstract
Zika virus (ZIKV) causes microcephaly by killing neural precursor cells (NPCs) and other brain cells. ZIKV also displays therapeutic oncolytic activity against glioblastoma (GBM) stem cells (GSCs). Here we demonstrate that ZIKV preferentially infected and killed GSCs and stem-like cells in medulloblastoma and ependymoma in a SOX2-dependent manner. Targeting SOX2 severely attenuated ZIKV infection, in contrast to AXL. As mechanisms of SOX2-mediated ZIKV infection, we identified inverse expression of antiviral interferon response genes (ISGs) and positive correlation with integrin αv (ITGAV). ZIKV infection was disrupted by genetic targeting of ITGAV or its binding partner ITGB5 and by an antibody specific for integrin αvβ5. ZIKV selectively eliminated GSCs from species-matched human mature cerebral organoids and GBM surgical specimens, which was reversed by integrin αvβ5 inhibition. Collectively, our studies identify integrin αvβ5 as a functional cancer stem cell marker essential for GBM maintenance and ZIKV infection, providing potential brain tumor therapy.Entities:
Keywords: Integrin αvβ5; Sox2; Zika; cancer stem cell; glioblastoma; glioblastoma stem cell; glioma; interferon; oncolytic virus; organoid
Mesh:
Substances:
Year: 2020 PMID: 31956038 DOI: 10.1016/j.stem.2019.11.016
Source DB: PubMed Journal: Cell Stem Cell ISSN: 1875-9777 Impact factor: 24.633